Company
Headquarters: Taipei, Taiwan
TW$1.23 Billion
TWD as of Jan. 1, 2024
US$40.2 Million
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $461.52 B |
| Vertex Pharmaceuticals Incorporated | $107.23 B |
| Regeneron Pharmaceuticals, Inc. | $100.01 B |
| CSL Limited | $94.74 B |
| Marinomed Biotech AG | $73.23 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
TWi Biotechnology, Inc., a clinical stage biopharmaceutical company, develops and sells drugs for innate immunity related diseases in Taiwan. It offers AC-203, which is in Phase 2 for various indications, including epidermolysis bullosa simplex, bullous pemphigoid, and epidermolysis bullosa (all types); AC-701 that is in Phase 2 to treat various inflammatory skin diseases; and AC-1101, which is in Phase 1 for the treatment of autoimmune inflammatory skin diseases. TWi Biotechnology, Inc. has a strategic partnership with Hongkong Winhealth Pharma Group granting Winhealth Pharma exclusive right to develop and commercialize rare disease asset AC-203 for various indications, including hereditary epidermolysis bullosa, bullous pemphigoid, and other skin diseases in Mainland China, Hong Kong, and Macao. The company was founded in 2010 and is based in Taipei, Taiwan. TWi Biotechnology, Inc. is a subsidiary of TWi Pharmaceuticals, Inc.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
TWi Biotechnology, Inc. has the following listings and related stock indices.
Stock: TWSE: 6610 wb_incandescent